News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mesoblast Limited Revascor Increases Blood Supply to Damaged Heart Muscle
June 9, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne, June 9, 2011 (ABN Newswire) - Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Asia
Australia
MORE ON THIS TOPIC
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
January 21, 2026
·
1 min read
·
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
Career Advice
Going With the Flow: Finding Success in Academic and Biotech Research Cultures
January 21, 2026
·
6 min read
·
Manali Shah
Cancer
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo
January 20, 2026
·
2 min read
·
Annalee Armstrong
